Cyclopharm (ASX: CYC) — Perfil da empresa, notícias e dados financeiros
Cyclopharm develops radiopharmaceuticals, including Technegas for functional lung ventilation imaging in nuclear medicine.
Cyclopharm
Cyclopharm is a radiopharmaceutical and medical technology company focused on pulmonary ventilation imaging and molecular diagnostic solutions. The company manufactures and distributes specialized nuclear medicine generators and single-use consumable sets used to produce structured carbon nano-particles for diagnostic lung imaging. Its core system assists in diagnosing pulmonary conditions, including pulmonary embolism, asthma, chronic obstructive pulmonary disease, and occupational lung diseases. Operating primarily under the Cyclomedica brand, the company maintains direct commercial networks and distribution partnerships serving hospitals, clinics, and research institutions across more than 65 countries globally.
Resumo
Operações
Produtos e/ou serviços de Cyclopharm
- Patient Consumables: Provision of recurring single-use patient administration sets and crucible consumable kits required for operating pulmonary ventilation imaging systems globally, generating recurring annuity stream revenues across nuclear medicine departments in over 65 countries worldwide.
- Ventilation Generator Equipment: Design, manufacture, and commercial sales of specialized nuclear medicine generator units that produce structured ultra-fine carbon nano-particles, enabling healthcare providers to perform three-dimensional diagnostic imaging of patient lung ventilation.
- United States Expansion: Direct commercial distribution, installation, and clinical onboarding of lung ventilation imaging systems across hospital networks and imaging facilities, targeting a market potential of 180 million USD across nuclear medicine diagnostic hubs.
- Third-Party Product Distribution: Regional sales, logistics, and agency distribution of complementary third-party radiopharmaceuticals, molecular imaging products, and specialized medical equipment, leveraging established regulatory and commercial channels across international diagnostic markets.
- Respiratory Indication Development: Clinical research programs, trial support, and regulatory development initiatives aimed at expanding diagnostic ventilation imaging applications beyond pulmonary embolism into asthma, chronic obstructive pulmonary disease, lung cancer, and silicosis.
- Technical Support and Servicing: Operational maintenance, regulatory compliance calibration, field technical servicing, and specialized staff training delivered across global customer locations to ensure equipment uptime and adherence to medical device quality standards.
equipe executiva do Cyclopharm
- James S. McBrayerCEO, MD, Company Secretary & Director
- Jason SmithChief Financial Officer
- Mathew FaragChief Operating Officer
- Sally-Ann CorneliusHead of Sales
- Niamh McAreeHead of Quality and Regulatory
- Chris QuinnHead of Service
- Sui Ling CheahFinancial Controller
- Lynn McLauchlinGeneral Manager of Canada
- Gary T. SomervilleQuality & Regulatory Manager
Últimas notícias sobre a Cyclopharm
Cyclopharm gains Chinese endorsement for Technegas imaging
AustraliaCyclopharm posts record $17.5M FY26 revenue
AustraliaAustralia's Cyclopharm secures 11-site agreement in US
AustraliaCyclopharm defers US guidance despite $17.1M revenue
AustraliaCyclopharm secures strategic US milestone agreement
AustraliaCyclopharm secures landmark 11-site agreement with UPHS
Australia
Comunicados recentes
O que a Cyclopharm (CYC) comunicou ao mercado, do mais recente para o mais antigo.
- Change in substantial shareholding from AEF
- Chinese Consensus Names Technegas Preferred Lung AgentFato relevante
Histórico de dividendos
Dividendos por ação pagos pela Cyclopharm, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2023 | A$0.0050 | A$0.0050 | — | A$0.0100 |
| FY2022 | A$0.0050 | A$0.0050 | — | A$0.0100 |
| FY2021 | A$0.0050 | A$0.0050 | — | A$0.0100 |
| FY2020 | A$0.0050 | A$0.0050 | — | A$0.0100 |
| FY2019 | A$0.0050 | A$0.0050 | — | A$0.0100 |
Principais indicadores financeiros
Resultados divulgados pela Cyclopharm, em AUD.
- Cap. de mercado
- 54,7 mi
- Receita (TTM)
- 34,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -53.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 32,3 mi | -18,2 mi | -17,2 mi | |
| 27,6 mi | -14,3 mi | -13,2 mi | |
| 26,3 mi | -5,3 mi | -4,7 mi | |
| 23,2 mi | -7,3 mi | -6,6 mi |